Details for Patent: 8,546,399
✉ Email this page to a colleague
Which drugs does patent 8,546,399 protect, and when does it expire?
Patent 8,546,399 protects VENCLEXTA and is included in one NDA.
This patent has one hundred and thirty-eight patent family members in forty-two countries.
Summary for Patent: 8,546,399
Title: | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Abstract: | Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. |
Inventor(s): | Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert (Franklin, WI), Hansen; Todd M. (Grayslake, IL) |
Assignee: | Abbvie Inc. (North Chicago, IL) |
Application Number: | 12/787,682 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,546,399 |
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 8,546,399
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,546,399
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 076705 | ⤷ Try a Trial | |||
Argentina | 079124 | ⤷ Try a Trial | |||
Argentina | 109974 | ⤷ Try a Trial | |||
Australia | 2010254160 | ⤷ Try a Trial | |||
Australia | 2010354083 | ⤷ Try a Trial | |||
Australia | 2015201117 | ⤷ Try a Trial | |||
Australia | 2015202183 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |